AWM
MYGN icon

Avior Wealth Management’s Myriad Genetics MYGN Stock Holding History

Avior Wealth Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16
Closed -$341 – 3169
2024
Q1 		$341 Buy
+16
New +$344 ﹤0.01% 2681

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Avior Wealth Management's MYGN Position: Q2 2024 in Review

Avior Wealth Management sold out of Myriad Genetics (MYGN) in Q2 2024, closing a stake of 16 shares — an estimated $341 sold.

Avior Wealth Management first reported a position in MYGN in Q1 2024 and held it in 1 quarter. The position peaked at $341 in Q1 2024. 223 funds tracked by Wall St. Rank hold MYGN as of Q2 2024.

  • Avior Wealth Management reported no remaining Myriad Genetics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 16 Myriad Genetics shares in Q2 2024, an estimated $341.
  • Avior Wealth Management first reported a position in Myriad Genetics in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Myriad Genetics position peaked at $341 in Q1 2024.
  • 223 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.